Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amylyx Pharmaceuticals wins orphan drug designation from FDA

By Brian Buntz | November 17, 2020

AmylyxThe neurodegenerative-diseased-focused biotech Amylyx Pharmaceuticals announced that it had received orphan drug designation for AMX0035, a proprietary blend of sodium phenylbutyrate and tauroursodeoxycholic acid.

The Cambridge, Mass.-based company won that designation to treat Wolfram syndrome, a rare genetic disease associated with diabetes, progressive optic atrophy, hearing loss and severe neurological disabilities. 

The prognosis for patients diagnosed with the disease is poor. Many Wolfram syndrome patients die by around 35 years of age.

“Wolfram is a debilitating syndrome in need of new treatments,” said Kent Leslie, global head of R&D and chief scientific officer at Amylyx.

The company began focusing on the syndrome after the mother of a patient connected with Wolfram syndrome expert Dr. Fumihiko Urano. The physician had been evaluating Amylyx compounds in his lab.

“Early evidence supports the potential of AMX0035 to target the underlying cellular pathology,” Leslie said. “The commitment to finding new potential therapies from the patients, caregivers and clinicians of this rare disease spearheaded this encouraging progress.”

There was no treatment for the disease until researchers identified that the endoplasmic reticulum membrane dysfunction is a hallmark of the disease. 

AMX0035 is intended to target endoplasmic reticulum stress, and preclinical data suggest that the drug could potentially stop optic nerve atrophy in Wolfram syndrome patients. 

“Orphan drug designation will support us as we explore AMX0035 in treating this rare and underserved population living with a life-threatening disease that has no approved therapies,” Leslie said.

The company is also investigating the use of AMX0035 to treat amyotrophic lateral sclerosis and Alzheimer’s disease.

Amylyx had announced that ALS patients receiving the drug had a 44% reduced mortality compared to trial volunteers who received placebo over a three-year period. The journal Muscle & Nerve published results from that study.  

“It has been inspiring to meet patients and families affected by Wolfram Syndrome,” concluded Josh Cohen, co-CEO and cofounder of Amylyx. 

“We will press ahead with their support and hope to enter clinical studies in the near future,” added Justin Klee, the other co-CEO and co-founder of the company. “We are committed to improving the lives of patients with Wolfram syndrome and know they are waiting.”

 


Filed Under: clinical trials, Drug Discovery, Neurological Disease, Orphan Drugs
Tagged With: ALS, Alzheimer's disease, AMX0035, Amylyx, Amylyx Pharmaceuticals, amyotrophic lateral sclerosis, Wolfram syndrome
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE